|
Post-drug administration adverse events experienced by individuals with single infection of W. bancrofti |
|||
| Clinical / Symptoms |
(Score) Peak intensity* |
Group C (Albendazole + Ivermectin, n = 12) (no. of individuals with symptom) |
Group D (Albendazole, n = 13) (no. individuals with symptom) |
|
|
|||
| Fever |
1.0 |
2 |
0 |
| Itching |
1.0 |
3 |
0 |
| Palpitation |
1.0 |
1 |
0 |
| Headache |
1.0 |
0 |
1 |
| Dizziness |
2.0 |
0 |
2 |
| Adenitis |
2.0 |
0 |
1 |
| Oedema |
2.0 |
0 |
1 |
| Chills |
NA |
0 |
0 |
| Lethargy |
NA |
0 |
0 |
| Myalgia |
NA |
0 |
0 |
| Anorexia |
NA |
0 |
0 |
|
Scores 0 = no alteration 1 = mild alteration, individual could conduct normal activities without symptom relief. 2 = moderate alteration, individual could proceed with normal daily activity after taking analgesic to alleviate events 3 = severe alteration, individual need be admitted hospital and treated for symptoms. *Mean of highest reaction score for each individual with this sign/symptom. 0, indicates normal, 1 indicates mild; 2 moderate; 3 severe, while fever: 0, indicates 37.0°C – 37.4°C, 1, indicates 37.5°C–37.7°C, 2 indicates 37.8°C–38.8°C, 3 indicates >38.8°C † Group A initially received a single dose of ivermectin (150 μg/kg) plus albendazole (400 mg). Group B received 6 saccharine tablets as a placebo. Five days later the treatment regime was administered in reverse, with the Group A receiving placebo and Group B receiving treatment. | |||
Makunde et al. Filaria Journal 2003 2:15 doi:10.1186/1475-2883-2-15 |
|||